Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome

Ruchi Mathur, Olga Levin, Ricardo Azziz, Ruchi Mathur, Olga Levin, Ricardo Azziz

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.

Keywords: PCOS; drospirenone; oral contraceptives; polycystic ovary syndrome; treatment.

Figures

Figure 1
Figure 1
Structure of drospirenone (1a) and spironolactone (1b).

References

    1. Armstrong VL, Wiggam MI, et al. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. QJM. 2001;94:31–7.
    1. Azziz R, Nestler JE, et al., editors. Androgen excess disorders in women, polycystic ovary syndrome and other disorders. 2. Totowa, New Jersey: Humana Press; 2006.
    1. Azziz R, Woods KS, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–9.
    1. Barth JH, Cherry CA, et al. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clinic Endocrinol(Oxf) 1991;35:5–10.
    1. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2006;85:436–40.
    1. Carlstrom K, Karlsson R, et al. Diurnal rhythm of and effects on oral contraceptives on serum dehydroepiandrosterone sulphate (DHEAS) are related to alterations in serum albumin rather than to changes in adrenocortical steroid secretion. Scand J Clini Lab Invest. 2002;62:361–8.
    1. Cassidenti DL, Paulson RJ, et al. Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstetrics and Gynecology. 1991;78:103–7.
    1. Cibula D, Fanta M, et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod. 2005;20:180–4.
    1. Cibula D, Sindelka G, et al. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum Reprod. 2002;17:76–82.
    1. Creatsas G, Koliopoulos C, et al. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci. 2000;900:245–52.
    1. Dahlgren E, Landin K, et al. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod. 1998;13:2706–11.
    1. De Leo V, Morgante G, Piomboni P, et al. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril. 2007;88:113–7.
    1. Dinger J, Heinemann L, et al. The safety of a drospirenone containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women – years of observation. Contraception. 2007;75:344–54.
    1. Elter K, Imir G, et al. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod. 2002;17:1729–37.
    1. Escobar-Morreale HF, Lasuncion MA, et al. Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil Steril. 2000;74:816–9.
    1. Falsetti L, Pasinetti E. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 1995;74:56–60.
    1. Guido M, Romualdi D, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89:2817–23.
    1. Hammerstein J, Meckies J, et al. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem. 1975;6:827–36.
    1. Kluft C, Endrikat J, et al. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 mcg ethinyl estradiol and a reference containing desogestrel and 30 mcg ethinyl estradiol. Contraception. 2006;73:336–43.
    1. Knochenhauer ES, Key TJ, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clinic Endocrinol Metab. 1998;83:3078–82.
    1. Korytkowski MT, Mokan M, et al. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:3327–34.
    1. Laven JSE, Imani B, et al. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv. 2002;57:755–67.
    1. Legro RS, Driscoll D, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 1998;95:14956–60.
    1. Lobo RA. Choice of treatment for women with polycystic ovary syndrome. Fertil Steril. 2006;86(Suppl 1):S22–3.
    1. Mastorakos G, Koliopoulos C, et al. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril. 2002;77:919–27.
    1. Mauvais-Jarvis P, Jayle MF, et al. In vivo studies on metabolism of androgens following administration of steroid inhibitors of ovulation. 1. Changes in the secretion of androgens and excretion of their metabolites in normal subjects and women with the Stein-Leventhal syndrome. Acta Endocrinologica. 1965;50:131–44.
    1. Michelmore KF, Balen AH, et al. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol. 1999;51:779–86.
    1. Moghetti P, Tosi F, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85:89–94.
    1. Morin-Papunen L, Vauhkonen I, et al. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003;88:148–56.
    1. Morin-Papunen LC, Vauhkonen I, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2000;85:3161–8.
    1. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod. 2007;22:317–22.
    1. Nader S, Riad-Gabriel MG, et al. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab. 1997;82:3074–7.
    1. Palep-Singh M, Mook K, et al. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care. 2004;30:163–5.
    1. Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2007;12:30–5.
    1. Pugeat M, Nicolas MH, et al. Androgens in polycystic ovarian syndrome. Ann N Y Acad Sci. 1993;687:124–35.
    1. van der Vange N, Blankenstein MA, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 1990;41:345–52.
    1. Venturoli S, Marescalchi O, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999;84:1304–10.
    1. Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update. 2005;11:277–91.
    1. Wiegratz I, Kutschera E, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. 2003;67:25–32.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren